login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Account
Disclaimer
Affiliate
Contact
Privacy
INCYTE CORP (INCY) Stock News
USA
- NASDAQ:INCY -
US45337C1027
-
Common Stock
83.1
USD
-3.07 (-3.56%)
Last: 9/12/2025, 8:00:02 PM
82.3301
USD
-0.77 (-0.93%)
After Hours:
9/12/2025, 8:00:02 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
INCY Latest News, Press Relases and Analysis
All
Press Releases
3 days ago - By: Chartmill
- Mentions:
LULU
CRL
PFE
KR
...
Uncover the latest developments among S&P500 stocks in today's session.
13 days ago - By: Chartmill
- Mentions:
APA
ALB
STZ
BG
...
Tuesday's session: top gainers and losers in the S&P500 index
5 days ago - By: Incyte
Incyte to Present New Data Highlighting Progress Across its Dermatology Pipeline at the European Association of Dermatology and Venerology 2025 Congress
12 days ago - By: Zacks Investment Research
- Mentions:
TGTX
Why Is TG Therapeutics (TGTX) Up 4.7% Since Last Earnings Report?
12 days ago - By: Incyte
Incyte Launches HS TRUTHS to Spotlight the True Lived Experience of Hidradenitis Suppurativa
17 days ago - By: MarketBeat
Can Incyte Deliver on 447% EPS Forecasts and Pipeline Hype?
17 days ago - By: Chartmill
Incyte Corp (NASDAQ:INCY): A Prime Candidate for Value Investors Seeking Undervalued Stocks
18 days ago - By: Zacks Investment Research
Incyte (INCY) Up 9.4% Since Last Earnings Report: Can It Continue?
18 days ago - By: Yahoo Finance
Incyte Corporation (INCY) Expands Precision Medicine with QIAGEN Partnership
19 days ago - By: Incyte
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
21 days ago - By: Incyte
Incyte Announces the Appointment of Soni Basi as Executive Vice President and Chief Human Resources Officer
24 days ago - By: Benzinga
13 Analysts Have This To Say About Incyte
24 days ago - By: Zacks Investment Research
- Mentions:
PFE
LLY
ABBV
AbbVie Pins Hopes on Rinvoq to Drive Next Phase of Growth
26 days ago - By: Zacks Investment Research
- Mentions:
NVS
QGEN
INCY Stock Trading Close to Its 52-Week High: Buy, Sell or Hold?
26 days ago - By: Yahoo Finance
Are Wall Street Analysts Predicting Incyte Stock Will Climb or Sink?
a month ago - By: Incyte
Incyte to Present at Upcoming Investor Conferences
a month ago - By: Yahoo Finance
- Mentions:
WFC
Wells Fargo Upgrades Incyte Corporation (INCY) to Overweight From Equal Weight
a month ago - By: Benzinga
Beyond The Numbers: 12 Analysts Discuss Incyte Stock
a month ago - By: Yahoo Finance
- Mentions:
WFC
UBS
MNDY
CACI
...
Snap downgraded, Leidos upgraded: Wall Street's top analyst calls
a month ago - By: Incyte
Incyte Announces Departure of Chief Financial Officer Christiana Stamoulis
a month ago - By: Investor's Business Daily
- Mentions:
GILD
AUPH
KNSA
Gilead Sciences Reports Earnings Thursday. Can The Highly Ranked Drugmaker Beat Its 237% Profit Surge Last Quarter?
a month ago - By: Stocktwits
- Mentions:
PKW
Barclays Initiates Incyte With Overweight Rating, $90 Price Target, Retail Finds Reason To Cheer
a month ago - By: Zacks Investment Research
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
Please enable JavaScript to continue using this application.